

(19) World Intellectual Property
Organization
International Bureau



549489

(43) International Publication Date
30 September 2004 (30.09.2004)

PCT

(10) International Publication Number
WO 2004/082630 A2

- (51) International Patent Classification⁷: **A61K**
- (21) International Application Number:
PCT/US2004/008120
- (22) International Filing Date: 17 March 2004 (17.03.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/455,405 17 March 2003 (17.03.2003) US
- (71) Applicant (for all designated States except US): **NEURO-HEALING PHARMACEUTICALS, INC.** [US/US]; 18 Dean Road, Suite #2, Brookline, MA 02445 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **KATZMAN, Daniel, E.** [AR/US]; 18 Dean Road, Suite #2, Brookline, MA 02445 (US). **GAMZU, Elkan, R.** [US/US]; 33 Nobscot Road, Newton, MA 02159 (US). **FARBER, Neal, M.** [US/US]; 1860 Beacon Street, Waban, MA 02468 (US). **FRIDMAN, Esteban, A.** [AR/AR]; Ortega y Gasset 1963, 4A, Capital Federal (AR). **MERELLO, Marcelo** [AR/AR]; Arenelas 832, Piso 4, Capital Federal (AR).
- (74) Agents: **YANKWICH, Leon, R.** et al.; Yankwich & Associates, 201 Broadway, Cambridge, MA 02139 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Declarations under Rule 4.17:**
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for all designations
 - of inventorship (Rule 4.17(iv)) for US only
- Published:**
- without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: HIGH POTENCY DOPAMINERGIC TREATMENT OF NEUROLOGICAL IMPAIRMENT ASSOCIATED WITH BRAIN INJURY

(57) Abstract: Methods and compositions are described for treating impaired neurological function, including altered state of consciousness disorders, in an individual who has sustained a brain injury comprising administering to the individual apomorphine. Methods and compositions are described for treating impaired neurological function, including altered state of consciousness disorders, in an individual who has sustained a brain injury comprising administering to the individual at least 1000mg or more of L-dopa (levodopa) per day. The use of potent dopaminergic agents to stimulate emergence from an altered consciousness state, such as a coma, is disclosed.

WO 2004/082630 A2